[The clinical significance of serum autoantibodies and HLA-B(27) molecule testing in Uygur patients with human immunodeficiency virus infection]

Objective: To explore the clinical value of serum autoantibodies and human leukocyte antigen (HLA-B(27)) molecular testing in Uygur patients with human immunodeficiency virus (HIV) infection. Method: A total of 727 HIV-infected Uygur patients who visited Kuche infectious diseases hospital during May 2016 to March 2017 were include in this study. The other 390 healthy people were enrolled as controls. Serum antinuclear antibodies (ANA), anti-cyclic citrullinated peptide (CCP) antibody, anti-extractable nuclear antigen (ENAs) antibody and HLA-B(27) molecule were tested. Result: Among 727 HIV-infected Uygur patients, 317 were males and 410 were females with mean age (35.52±13.44) years old. The mean duration of disease was (6.34±3.05) years. There were 697 (95.87%) patients receiving highly active antiretroviral therapy (HAART) with mean duration of treatment (5.52±3.47) years. The mean CD4(+)T cell count was (520±271) cells/μl in 202 HIV-infected patients, and mean virus load was (108 139±20 498) copies/ml in 20 HIV-infected patients. Rheumatic manifestations were recorded in 238 (32.74%) HIV-infected Uygur patients, mainly with dry mouth and dry eye (15.41%) , alopecia (9.90%) , arthralgia (8.94%) , ect. Compared with the health controls, positive ANA was more common in HIV infected Uygur patients (33.43% vs. 17.43%, P<0.001) with low titers (ANA titer:1∶100) . HIV-infected Uygur patients had higher positive anti-u1-RNP antibodies positive rate (1.10%), but lower anti-SSA antibodies positive rate (0.14%) and anti-CCP antibodies positive rate (0.28%). Patients with positive ANA in HAART group were significantly less than that in non-treatment group (32.71% vs. 50.00%, P=0.049). There were no correlations between ANA and duration of HAART, CD4(+)T cell counts and virus load (r values 0.061, 0.047, 0.121, respectively. P>0.05). Only one female patient was HLA-B(27) positive (0.14%), which was significantly lower than that in healthy controls (3.08%) (P<0.001). Also, only one patient was diagnosed with rheumatoid arthritis (RA). Conclusion: Autoimmune manifestations are common in HIV-infected Uygur patients. Several autoantibodies are positive, but the coincidence of rheumatic diseases is rare. It's noted that patients with autoimmune manifestations should be considered as a differential diagnosis of HIV infection.

Enhanced visible light absorption performance of SnS2 and SnSe2 via surface charge transfer doping

The layered two-dimensional (2D) SnS₂ and SnSe₂ have received intensive attention due to their sizable band gaps and potential properties. However, it has been shown that the visible light absorption of SnS₂ and SnSe₂ are restricted as photocatalysts and light-harvesting material absorbers for water splitting and high-performance optoelectronic devices. Herein, to enhance the visible light absorption performance of SnS₂ and SnSe₂, we performed a systematic investigation on tuning the electronic and optical properties of monolayers SnS₂ and SnSe₂ via surface charge transfer doping (SCTD) with the adsorption of molybdenum trioxide (MoO₃) and potassium (K) as surface dopants based on density functional theory. Our calculations reveal that MoO₃ molecules and K atoms can draw/donate electrons from/to SnS₂ and SnSe₂ as acceptors and donors, respectively. The adsorption of MoO₃ molecules introduces a new flat impurity state in the gap of the monolayers SnS₂/SnSe₂, and the Fermi level moves correspondingly to the top of valence band, resulting in a p-type doping of the monolayer SnS₂/SnSe₂. With the adsorption of K atoms, the electrons can transfer from K atoms to the monolayer of SnS₂ and SnSe₂, making K an effective electron-donating dopant. Meanwhile, the bandgaps of monolayers SnS₂ and SnSe₂ decrease after the MoO₃ and K doping, which leads to the appearance of appreciable new absorption peaks at around ∼650/480 and ∼600/680 nm, respectively, and yielding an enhanced visible light absorption of SnS₂ and SnSe₂. Our results unveil that SCTD is an effective way to improve the photocatalytic and light-harvesting performance of SnS₂ and SnSe₂, broadening their applications in splitting water and degrading environmental pollutants under sunlight irradiation.

The improvement of photocatalytic activity of monolayer g-C3N4via surface charge transfer doping

Graphite-like carbon nitride (g-C₃N₄) has attracted much attention due to its peculiar photocatalytic performance as a visible-light-responsive photocatalyst. However, its insufficient sunlight absorption is not conducive to the photocatalytic activity of the g-C₃N₄. Herein, by using first-principles density functional theory (DFT) calculations, we demonstrated a simple yet efficient way to achieve improvement of photocatalytic activity of monolayer g-C₃N₄via surface charge transfer doping (SCTD) using the electron-drawing tetracyanoquinodimethane (TCNQ) and electron-donating tetrathiafulvalene (TTF) as surface dopants. Our calculations revealed that the electronic properties of monolayer g-C₃N₄ can be affected by surface modification with TCNQ and TTF. These dopants are capable of drawing/donating electrons from/to monolayer g-C₃N₄, leading to the accumulation of holes/electrons injected into the monolayer g-C₃N₄. Correspondingly, the Fermi levels of monolayer g-C₃N₄ were shifted towards the valence/conduction band regions after surface modifications with TCNQ and TTF, along with the increase/decrease of work functions. Moreover, the optical property calculations demonstrated that the TCNQ and TTF modifications could significantly broaden the optical absorption of monolayer g-C₃N₄ in the visible-light regions, yielding an improvement in the photocatalytic activity of monolayer g-C₃N₄. Our results unveil that SCTD is an effective way to tune the electronic and optical properties of monolayer g-C₃N₄, thus improving its photocatalytic activity and broadening its applications in splitting water and degrading environmental pollutants under sunlight irradiation.

The improvement of optical adsorption for monolayer g-C₃N₄via surface charge transfer doping.

Application of oxaliplatin in combination with epirubicin in transcatheter arterial chemoembolization in the treatment of primary liver carcinoma

Many cases of liver carcinoma miss the opportunity of surgical treatment because of hidden onset and delayed diagnosis. In recent years, interventional treatment has gradually become a non-surgical method for treating liver carcinoma. To discuss the effects of oxaliplatin in combination with epirubicin in the treatment and its influence on prognosis, this study randomly selected 218 advanced primary liver carcinoma patients from Binzhou People’s Hospital, Binzhou, China and divided them into a control group (n=109) and an observation group (n=109). Patients in both groups were given interventional treatment. Patients in the control group were perfused with oxaliplatin, while patients in the observation group were perfused with oxaliplatin and epirubicin. The effectsat 6-month and 12-month survival rates were compared between the two groups. The results demonstrated that the overall effective rate and clinical benefit rate of the observation group were much higher than those of the control group (30.3% vs 11.9%; 79.8%; vs 44.3%) (P less than 0.05). The serum Alpha Fetal Protein (AFP) and Carcino Embryonie Antigen (CEA) levels of the observation group were much lower than those of the control group; the Karnofsky performance score of the observation group was much lower than that of the control group; the two differences had statistical significance (P less than 0.05). The 6-month survival rate of the observation group was 91.67%, higher than that of the control group (86.11%) (P>0.05). The 12-month survival rate of the observation group was 83.33%, much higher than that of the control group (61.11%) (P less than 0.05). The difference of the incidence of adverse reactions between the two groups had no statistical significance (P>0.05). Thus, it can be concluded that oxaliplatin in combination with epirubicin can improve survival quality, extend survival time, and decrease the serum AFP and CEA levels in the treatment of primary liver carcinoma, with definite effects but without aggravating toxic and side effects. Therefore, the therapy has important clinical value.